LABIANA HEALTH S.A.EO-10 (8RK) - Total Liabilities
Based on the latest financial reports, LABIANA HEALTH S.A.EO-10 (8RK) has total liabilities worth €50.77 Million EUR (≈ $59.36 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
LABIANA HEALTH S.A.EO-10 - Total Liabilities Trend (2021–2024)
This chart illustrates how LABIANA HEALTH S.A.EO-10's total liabilities have evolved over time, based on quarterly financial data. See LABIANA HEALTH S.A.EO-10 (8RK) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
LABIANA HEALTH S.A.EO-10 Competitors by Total Liabilities
The table below lists competitors of LABIANA HEALTH S.A.EO-10 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cobre Ltd
AU:CBE
|
Australia | AU$6.80 Million |
|
AmeriServ Financial Inc
NASDAQ:ASRV
|
USA | $1.35 Billion |
|
Everbrite Technology Co Ltd
TWO:4523
|
Taiwan | NT$2.22 Billion |
|
Hwang-Kum Stee
KO:032560
|
Korea | ₩110.61 Billion |
|
Chungdamglobal Co. Ltd.
KQ:362320
|
Korea | ₩97.11 Billion |
|
Prolific Technology
TWO:6233
|
Taiwan | NT$134.23 Million |
|
Softtech Engineers Limited
NSE:SOFTTECH
|
India | Rs831.31 Million |
|
CHANJET INFO.TECHN.-H-YC1
F:C7D
|
Germany | €936.82 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down LABIANA HEALTH S.A.EO-10's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see LABIANA HEALTH S.A.EO-10 market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 12.93 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.93 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LABIANA HEALTH S.A.EO-10's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LABIANA HEALTH S.A.EO-10 (2021–2024)
The table below shows the annual total liabilities of LABIANA HEALTH S.A.EO-10 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €49.43 Million ≈ $57.79 Million |
-11.28% |
| 2023-12-31 | €55.72 Million ≈ $65.14 Million |
+3.43% |
| 2022-12-31 | €53.87 Million ≈ $62.98 Million |
-5.23% |
| 2021-12-31 | €56.84 Million ≈ $66.46 Million |
-- |
About LABIANA HEALTH S.A.EO-10
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, North America, rest of European Union, and internationally. The company offers anesthetics-sedative, anti-infective, anti-inflammatory, antiparasitic, hormonal, and nutritional products; metabolism regulators; and vitamin products. It also provides sterile, lyophilized dosage forms,… Read more